Trial Profile
A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Allergic RhinoConjunctivitis Without or With Controlled Asthma using a Titrated Nasal Provocation Test model.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2020
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Lofarma S.p.A
- 16 Jul 2020 Status changed from recruiting to completed.
- 31 Aug 2018 New trial record